Results 11 to 20 of about 456 (124)

<i>TAC1b</i> mutation in <i>Candida auris</i> decreases manogepix susceptibility owing to increased <i>CDR1</i> expression. [PDF]

Antimicrob Agents Chemother
Candida auris is an emerging pathogenic fungus that is highly resistant to existing antifungal drugs. Manogepix is a novel antifungal agent that exerts antifungal activity by inhibiting glycosylphosphatidylinositol anchor biosynthesis.
Hirayama T, Miyazaki T, Tanaka R, Kitahori N, Yoshida M, Takeda K, Ide S, Iwanaga N, Tashiro M, Takazono T, Izumikawa K, Yanagihara K, Makimura K, Tsukamoto K, Mukae H.   +14 more
europepmc   +5 more sources

Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro. [PDF]

Antimicrob Agents Chemother, 2023
Candida auris is an emerging, multidrug-resistant fungal pathogen that causes refractory colonization and life-threatening, invasive nosocomial infections. The high proportion of C.
John LLH, Thomson DD, Bicanic T, Hoenigl M, Brown AJP, Harrison TS, Bignell EM.   +6 more
europepmc   +7 more sources

The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo. [PDF]

Med Mycol, 2023
Mycetoma is a neglected tropical disease commonly caused by the fungus Madurella mycetomatis. Standard treatment consists of extensive treatment with itraconazole in combination with surgical excision of the infected tissue, but has a low success rate ...
Konings M, Eadie K, Strepis N, Nyuykonge B, Fahal AH, Verbon A, van de Sande WWJ.   +6 more
europepmc   +7 more sources

TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression [PDF]

TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression
Candida auris is an emerging pathogenic fungus that is highly resistant to existing antifungal drugs. Manogepix is a novel antifungal agent that exerts antifungal activity by inhibiting glycosylphosphatidylinositol anchor biosynthesis.
34876, Hirayama, Tatsuro, Ide, Shotaro, Iwanaga, Naoki, Izumikawa, Koichi, Kitahori, Natsume, Makimura, Koichi, Miyazaki, Taiga, Mukae, Hiroshi, Takazono, Takahiro, Takeda, Kazuaki, Tanaka, Rina, Tashiro, Masato, Tsukamoto, Kazuhiro, Yanagihara, Katsunori, Yoshida, Masataka, ミヤザキ, タイガ, 宮崎, 泰可   +17 more
core   +3 more sources

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. [PDF]

J Antimicrob Chemother, 2023
Safety; Antifungal; CandidaemiaSeguridad; Antifúngico; CandidemiaSeguretat; Antifúngic; CandidèmiaBackground Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including ...
Pappas PG, Vazquez JA, Oren I, Rahav G, Aoun M, Bulpa P, Ben-Ami R, Ferrer R, Mccarty T, Thompson GR, Schlamm H, Bien PA, Barbat SH, Wedel P, Oborska I, Tawadrous M, Hodges MR.   +16 more
europepmc   +3 more sources

Invasive Mould Infections Following Combat-Related Injuries-A Retrospective Cohort Study. [PDF]

Mycoses
ABSTRACT Background Available data on combat wound‐related invasive mould infections (IMIs) are limited. Objectives We aimed to describe the characteristics and outcomes of IMIs in casualties of a recent conflict. Patients/Methods A retrospective study including hospitalised patients with combat‐related injuries, fulfilling criteria for wound‐related ...
Hoffman T, Haviv Y, Cohen A, Nesher L, Schlaeffer-Yosef T, Azulay H, Brosh-Nissimov T, Amit S, Gazit Z, Tribble DR, Ben-Ami R, Yahav D.   +11 more
europepmc   +2 more sources

Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Manogepix (MGX) targets the conserved fungal Gwt1 enzyme required for acylation of inositol early in the glycosylphosphatidylinositol biosynthesis pathway. The prodrug fosmanogepix is currently in clinical development for the treatment of invasive fungal infections.
Kapoor, Mili, Moloney, Molly, Soltow, Quinlyn A., Pillar, Chris M., Shaw, Karen Joy   +4 more
openaire   +5 more sources

In vitro manogepix susceptibility testing of South African Emergomyces africanus, Emergomyces pasteurianus, and Blastomyces emzantsi clinical isolates. [PDF]

Antimicrob Agents Chemother, 2023
ABSTRACT We performed in vitro antifungal susceptibility testing of manogepix against the yeast phase of 78 Emergomyces africanus , 2 Emergomyces pasteurianus, and 5 Blastomyces emzantsi isolates using a reference broth microdilution ...
Nzimande SP, Govender NP, Maphanga TG.
europepmc   +3 more sources

In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak [PDF]

Antimicrobial Agents and Chemotherapy, 2020
An ongoing Candida auris outbreak in the New York metropolitan area is the largest recorded to date in North America. Laboratory surveillance revealed NY C. auris isolates are resistant to fluconazole, with variable resistance to other currently used ...
YanChun Zhu, Shannon Kilburn, Mili Kapoor, Sudha Chaturvedi, Karen Joy Shaw, Vishnu Chaturvedi   +5 more
openaire   +3 more sources

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician. [PDF]

, 2023
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-hospital morbidity and mortality. The limited number of antifungal drug classes and the emergence of multi-resistant Candida species, such as Candida auris and ...
Lamoth, F.
core   +1 more source